Does Glucomannan Cause Weight Loss? What the EFSA Claim Misses

By Erin Rose · Updated July 19, 2026 · Methodology

Informational summary of published research and EU regulatory text — not medical advice. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

What the EFSA claim actually says and requires

The authorized claim (EFSA NDA Panel scientific opinion, Regulation (EU) No 432/2012) states that glucomannan contributes to weight loss in the context of an energy-restricted diet, with conditions of use of 3 g glucomannan per day, taken in three doses of 1 g each with 1–2 glasses of water, before meals. Read that condition again: in the context of an energy-restricted diet. This is not a claim that glucomannan, taken on its own without dietary change, causes weight loss. It's a claim about glucomannan's role as a satiety aid alongside caloric restriction — and that distinction is exactly where the marketing usually goes further than the regulation does.

The null result: Keithley 2013

Keithley 2013 is the most methodologically clean modern weight-loss RCT in glucomannan's evidence base — registered (NCT00613600), double-blind, placebo-matched capsules, a pre-specified primary endpoint of body-weight change. Overweight and moderately obese adults (n=53, BMI 25–35) took 1.33g glucomannan with 8oz water one hour before each meal (~4g/day total) for 8 weeks. The result, quoted directly from the paper: "At 8 weeks, there was no significant difference between the glucomannan and placebo groups in amount of weight loss (-0.4 ± .06 and -0.43 ± .07, resp.) or other efficacy outcomes or in any of the safety outcomes." The authors' conclusion is equally direct: glucomannan "did not promote weight loss or significantly alter body composition, hunger/fullness, or lipid and glucose parameters." This trial tested a dose close to the EFSA protocol, with water, before meals — the pieces of the claim that are testable without a prescribed energy-restricted diet — and still found nothing.

The meta-analysis view: Onakpoya 2014 vs. the Sood 2008 outlier

Onakpoya 2014, an independent (University of Exeter) systematic review and meta-analysis, pooled 8 RCTs and found "a nonstatistically significant difference in weight loss between glucomannan and placebo (mean difference: -0.22 kg; 95% confidence interval, −0.62, 0.19; I² = 65%)." Their conclusion: "The evidence from available RCTs does not show that glucomannan intake generates statistically significant weight loss." The I²=65% heterogeneity is a real limitation worth naming, not just a caveat — it means the included trials didn't agree closely with each other, which weakens confidence in any pooled estimate either direction.

Contrast that with the older Sood 2008 meta-analysis (14 studies, n=531), which found a weighted mean weight-loss difference of -0.79 kg that does reach statistical significance. This is the number weight-loss marketing tends to cite. But it's the outlier against the two later, more targeted weight-loss reviews — likely reflecting an older, more heterogeneous trial pool that included combination-fiber studies and shorter or lower-quality trials that Onakpoya's stricter, more recent review excluded. When two purpose-built weight-loss reviews (one RCT, one meta-analysis) agree on null, and one broader, older, mixed-purpose meta finds a small positive, the honest read weights the former more heavily.

The honest verdict: a real mechanism that doesn't reliably become weight loss

Glucomannan's satiety mechanism is not fabricated or theoretical. Au-Yeung 2018, a randomized crossover trial, found that a gelled meal delivering 8g of konjac fibre (its "100-KGM" arm, where konjac-gel noodles replaced 100% of a pasta preload) cut cumulative energy intake -47% (1761 kJ / 421 kcal) compared with control in a single meal, and a 4g-fibre meal (the "50-KGM" arm) cut it 23% — both highly significant (P<0.001), and clearly dose-dependent. This is exactly the mechanism that makes the EFSA claim plausible in the first place: a highly viscous fiber that gels in the stomach and genuinely reduces how much you eat at the next sitting.

But notice the gap between that finding and a retail glucomannan supplement. Au-Yeung's meals delivered 4–8g of konjac fibre — only modestly above a typical 3–4g daily dose — but eaten as a gelled-noodle meal (a food, ~97% water), and the trial measured a single meal, not weight over weeks. The mechanism is real; what doesn't follow is that a normal 3g/day capsule or powder dose reliably reproduces that effect meal after meal, day after day, for long enough to show up on a scale — and the two trials that actually measured sustained weight change at realistic doses (Keithley 2013, 8 weeks; Onakpoya's pooled 8 RCTs) found that it didn't. That's the honest verdict: real appetite mechanism, unproven sustained weight-loss outcome. Buy glucomannan for its better-supported cholesterol effect if that's your goal; don't expect the scale to move meaningfully on the EFSA claim alone, without the energy-restricted diet the claim itself requires.

As an Amazon Associate we earn from qualifying purchases. Take with a full glass of water — see the dosage guide.

Frequently asked questions

Related

• Glucomannan for Cholesterol — the better-supported effect
• Dosage Guide — the EFSA protocol and the water rule
• Best Glucomannan Supplement — ranked by cost per gram
• All Glucomannan Guides
• Is Berberine "Nature's Ozempic"? — the site's other honest-rigor metabolic-claim page

Sources